BioSig Says Subsidiary Was Selected To Join NVIDIA Inception Program To Support R&D Collaboration On AI Medical Device Platform For Hospitals
Portfolio Pulse from Benzinga Newsdesk
BioSig Technologies announced that its subsidiary, ViralClear Pharmaceuticals, has been selected to join the NVIDIA Inception program. This partnership will support research and development collaboration on an AI medical device platform for hospitals.
July 20, 2023 | 11:13 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioSig's subsidiary, ViralClear Pharmaceuticals, joining the NVIDIA Inception program could potentially boost BioSig's profile and open up new opportunities in the AI medical device market.
The partnership with NVIDIA, a leader in AI, could potentially enhance BioSig's capabilities in developing AI medical devices. This could lead to new opportunities and potentially increase the company's market share in the healthcare sector.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
NVIDIA's partnership with BioSig's subsidiary, ViralClear Pharmaceuticals, could potentially enhance NVIDIA's presence in the healthcare sector.
The partnership with BioSig's subsidiary could potentially enhance NVIDIA's presence in the healthcare sector. This could lead to new opportunities and potentially increase the company's market share in this sector.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70